MedTrace Logo

Advancing Stillbirth Prevention Through Innovative Risk Evaluation (ASPIRE) Clinical Study

NCT07669935 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 5500

Last updated 2026-06-29

No results posted yet for this study

Summary

ASPIRE will be a multi-site, prospective, two-part longitudinal, noninterventional observational cohort study of nulliparous singleton pregnant women to evaluate biomarkers from blood and ocular imaging for prediction of pregnancy complications \[i.e., preeclampsia (PE), fetal growth restriction (FGR), and gestational diabetes (GDM)\] and risk of adverse outcomes.

Conditions

  • GDM
  • Preterm Preeclampsia
  • Preeclampsia
  • Fetal Growth Restriction (FGR)
  • Pregnancy Complications

Interventions

OTHER

None (this is an observational study with no intervention)

This is an observational study evaluating biomarkers from blood and ocular imaging for prediction of pregnancy complications and associated risks \[i.e., preeclampsia (PE), fetal growth restriction (FGR), and gestational diabetes (GDM)\].

Sponsors & Collaborators

  • Medicines360

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-07-30
Primary Completion
2028-07-01
Completion
2028-12-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07669935 on ClinicalTrials.gov